Plasma protein (albumin) catabolism by the tumor itself - Implications for tumor metabolism and the genesis of cachexia

Critical Reviews in Oncology/Hematology

Volumn 26, Issue 2, 1997, Pages 77-100

  Stehle, Gerd ^a,b   Sinn, Hannsjörg ^b   Wunder, Andreas ^a   Schrenk, Hans Hermann ^b   Stewart, J Charles M ^c   Hartung, Gernot ^a   Maier Borst, Wolfgang ^b   Heene, Dieter Ludwig ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c Scotia Pharmaceuticals   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; ALBUMIN; NITROGEN; OXYGEN; PLASMA PROTEIN; PROTEASOME; UBIQUITIN;

CACHEXIA; CANCER CELL; CELL METABOLISM; HUMAN; LIVER FUNCTION; LYSOSOME; NONHUMAN; PROTEIN DEGRADATION; PROTEIN SYNTHESIS; REVIEW; STARVATION;

ANIMALS; BLOOD PROTEINS; CACHEXIA; ENERGY METABOLISM; HUMANS; LIVER; LYSOSOMES; MODELS, BIOLOGICAL; NEOPLASMS; NITROGEN; OXYGEN CONSUMPTION; SERUM ALBUMIN;

EID: 0030842545     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1040-8428(97)00015-2     Document Type: Review

References (255)

1. 2 power of blood passing through a tumor. J Biol Chem 1926;66:397-405.
2. Warburg O, Wind F, Negelein E. The metabolism of tumors in the body. J Gen Physiol 1927;8:519-30.
3. Warburg O, Über den Stoffwechsel der Carcinomzelle, In: Warburg O, editor. Über den Stoffwechsel der Tumoren. Berlin, Heidelberg: Springer Verlag, 1926:187-193.
4. Mider GB, Tesluk H, Morton JJ. Effects of Walker carcinoma 256 on food intake, body weight and nitrogen metabolism of growing rats. Acta Union Int Contra Cancrum 1948;6:409-20.
5. Le Page GA, Potter VR, Heidelberger C, Hurlbert RB. Growth of carcinoma implants in fed and fasted rats. Cancer Res 1952;12:153-7.
6. Babson AL, Winnick T. Protein transfer in tumor-bearing rats. Cancer Res 1954;14:606-11.
7. Ryser HJ. The measurement of 131-iodine-serum albumin uptake by tumor cells in tissue culture. Lab Invest 1963;12:1009-17.
8. Busch H, Green HSN. Studies on the metabolism of plasma proteins in tumor bearing rats. Yale J Biol Med 1954;27:339-49.
9. Cohen S, Beiser SM, Hsu KH. Immunohistochemical study on the uptake of serum proteins by neoplastic liver cells. Cancer Res 1960;21:1510-4.
10. Busch H, Fuchiwara E, Firsze DC. Studies on the metabolism of radioactive albumin in tumor bearing rats. Cancer Res 1961;21:371-7.
11. 3H ascites albumin by Yoshida ascites tumor cells. Z Krebsforsch Klin Onkol 1969;72:305-11.
12. Mego JL, McQueen JD. The uptake of labeled proteins by particulate fractions of tumor and normal tissues after injection into mice. Cancer Res 1965;25:865-9.
13. Easty GC, Yarnell MM, Andrews RD. The uptake of proteins by normal and tumor cells in vitro. Br J Cancer 1964;18:354-7.
14. Rossing N. Albumin metabolism in neoplastic diseases. Scand J Clin Lab Invest 1968;22:211-6.
15. Jewell WR, Krishnan EC, Schloerb PR. Apparent ingress of albumin in Walker 256 tumor and rat muscle. Cancer Res 1975;35:405-8.
16. Costa G. Cachexia, the metabolic component of neoplastic disease. Cancer Res 1977;37:2327-35.
17. Brennan MF, Burt ME. Nitrogen metabolism in cancer patients. Cancer Treat Rep 1981:65:67-78.
18. Theologides A. Pathogenesis of cachexia in cancer, a review and a hypothesis. Cancer 1972;20:484-8.
19. Brennan MF. Uncomplicated starvation versus cancer cachexia. Cancer Res 1977;37:2359-64.
20. DeWys WD. Anorexia as a general effect of cancer. Cancer 1979;43:2013-9.
21. Theologides A. Cancer cachexia. Cancer 1979;43:2004-12.
22. Garattini S, Bizzi A, Donelli MG, Guaitani A, Samanin R, Spreafico F. Anorexia and cancer in animals and man. Cancer Treat Rev 1980;7:115-40.
23. DeWys WD. Pathophysiology of cancer cachexia: current understanding and areas for future research. Cancer Res 1982;42:721s-6s.
24. Lawson DH, Richmond A, Nixon DW, Rudman D. Metabolic approaches to cancer cachexia. Annu Rev Nutr 1982;2:277-301.
25. Jeevanandam M, Horowitz GD, Lowry SF, Brennan MF. Cancer cachexia and protein metabolism. Lancet 1984;1:1423-6.
26. Norton JA, Peacock JL, Morrison SD. Cancer cachexia. Crit Rev Oncol Hematol 1987;7:289-327.
27. Kern KA, Norton JA. Cancer cachexia. J Parenter Enteral Nutr 1988;12:286-98.
28. Torosian MH, Nguyen HQ. Tumors - effective nitrogen traps independent of protein intake. J Surg Res 1989;47:456-9.
29. Morrison SD. Cancer cachexia, In: Liotta LA ed. Influence of tumor development on the host. Dordrecht: Kluwer Academic, 1989:176-213.
30. Douglas RG, Shaw JH. Metabolic effects of cancer see comments. Br J Surg 1990;77:246-54.
31. Beck SA, Mulligan HD, Tisdale MJ. Lipolytic factors associated with murine and human cancer cachexia. J Natl Cancer Inst 1990;82:1922-6.
32. Lowry SF. Cancer cachexia revisited: old problems and new perspectives [editorial comment]. Eur J Cancer 1991;27:1-3.
33. Tisdale MJ. Cancer cachexia [editorial]. Br J Cancer 1991;63:337-42.
34. Fearon KC. The Sir David Cuthbertson Medal Lecture 1991. The mechanisms and treatment of weight loss in cancer. Proc Nutr Soc 1992;51:251-65.
35. McNamara MJ, Alexander HR, Norton JA. Cytokines and their role in the pathophysiology of cancer cachexia. J Parenter Enteral Nutr 1992;16:50S-5S.
36. Moldawer LL, Rogy MA, Lowry SF. The role of cytokines in cancer cachexia. J Parenter Enteral Nutr 1992;16:43S-9S.
37. Mulligan HD, Beck SA, Tisdale MJ. Lipid metabolism in cancer cachexia. Br J Cancer 1992;66:57-61.
38. Tisdale MJ. Cancer cachexia. Anti-Cancer Drugs 1993;4:115-25.
39. Espat NJ, Copeland EM, Moldawer LL. Tumor necrosis factor and cachexia: a current perspective. Surg Oncol 1994;3:255-62.
40. Nelson KA, Walsh D, Sheehan FA. The cancer anorexiacachexia syndrome. J Clin Oncol 1994;12:213-25.
41. Sinn H, Schrenk HH, Friedrich EA, Via DP, Dresel HA. Radioiodination of proteins and lipoproteins using N-bromosuccinimide as oxidizing agent. Anal Biochem 1988;170:186-92.
42. Ehrenreich BA, Cohn ZA. The uptake and digestion of iodinated serum albumin by macrophages in vitro. J Exp Med 1967;126:941-9.
43. De Nardo GL, De Nardo SJ, Miyao NP, et al. Non-dehalogenation mechanisms for excretion of radioiodine after administration of labeled antibodies. Int J Biol Markers 1988;3:1-9.
44. Hnatowich DJ. Recent developments in the radiolabeling of antibodies with iodine, indium, and technetium. Semin Nucl Med 1990;20:80-91.
45. Geissler F, Anderson SK, Venkatesan P, Press O. Intracellular catabolism of radiolabeled anti-mu antibodies by malignant B-cells. Cancer Res 1992;52:2907-15.
46. Van Zile J, Henderson LA, Baynes JW, Thorpe SR. 3HRaffinose, a novel radioactive label for determining organ sites of catabolism of proteins in the circulation. J Biol Chem 1979;254:3547-53.
47. Pittman RC, Carew TE, Glass CK, Green SR, Taylor CAJ, Attie AD. A radioiodinated, intracellularly trapped ligand for determining the sites of plasma protein degradation in vivo. Biochem J 1983;212:791-800.
48. Thorpe SR, Baynes JW, Chroneos ZC. The design and application of residualizing labels for the studies of protein catabolism. FASEB J 1993;7:399-405.
49. Strobel JL, Cady SG, Borg TK, Terracio L, Baynes JW, Thorpe SR. Identification of fibroblasts as a major site of albumin catabolism in peripheral tissues. J Biol Chem 1986;261:7989-94.
50. Henderson LA, Baynes JW, Thorpe SR. Identification of the sites of IgG catabolism in the rat. Arch Biochem Biophys 1982;215:1-11.
51. 125I]dilactitol tyramine. J Biol Chem 1985;260:14564-70.
52. Chroneos ZC, Baynes JW, Thorpe SR. Identification of liver endothelial cells as the primary site of IgM catabolism in the rat. Arch Biochem Biophys 1995;319:63-73.
53. Sinn H, Schrenk HH, Friedrich EA, Schilling U, Maier Borst W. Design of compounds having an enhanced tumour uptake, using serum albumin as a carrier - Part I. Int J Rad Appl Instrum B 1990;17:819-27.
54. Schilling U, Friedrich EA, Sinn H, Schrenk HH, Clorius JH, Maier Borst W. Design of compounds having enhanced tumour uptake, using serum albumin as a carrier-Part II. In vivo studies. Int J Rad Appl Instrum 1992;B19:685-95.
55. 111In]diethylenetriaminepentaacetic acid-monoclonal antibodies and antibody fragments in vivo. Cancer Res 1995;55:5714s-20s.
56. Andersson C, Iresjo BM, Lundholm K. Identification of tissue sites for increased albumin degradation in sarcoma-bearing mice. J Surg Res 1991;50:156-62.
57. Stein R, Goldenberg DM, Thorpe SR, Basu A, Mattes MJ. Effects of radiolabeling monoclonal antibodies with a residualizing iodine radiolabel on the accretion of radioisotope in tumors. Cancer Res 1995;55:3132-9.
58. Lehninger AL, Nelson DL, Cox MM. Principles of Biochemistry. New York: Worth, 1994.
59. 13C]leucine. Cancer Res 1995;55:1160-7.
60. Holm E, Hagmüller E, Staedt U, et al. Substrate balances across colonie carcinomas in humans. Cancer Res 1995;55:1373-8.
61. Kallinowski F, Vaupel P, Runkel S, et al. Glucose uptake, lactate release, ketone body turnover, metabolic micromilieu, and pH distributions in human breast cancer xenografts in nude rats. Cancer Res 1988;48:7264-72.
62. Inculet RI, Peacock JL, Gorschboth CM, Norton JA. Gluconeogenesis in the tumor-influenced rat hepatocyte: importance of tumor burden, lactate, insulin, and glucagon. J Natl Cancer Inst 1987;79:1039-46.
63. Richtsmeier WJ, Dauchy R, Sauer LA. In vivo nutrient uptake by head and neck cancers. Cancer Res 1987;47:5230-3.
64. Kallinowski F, Schlenger KH, Kloes M, Stohrer M. Vaupel P. Tumor blood flow: the principal modulator of oxidative and glycolytic metabolism, and of the metabolic micromilieu of human tumor xenografts in vivo. Int J Cancer 1989;44:266-72.
65. 2 tension measurements. Cancer Res 1991;51:3316-22.
66. Brown RR, Ozaki Y, Datta SP, Borden EC, Sondel PM, Malone DG. Implications of interferon-induced tryptophan catabolism in cancer, auto-immune diseases and AIDS. Adv Exp Med Biol 1991;294:425-35.
67. Chance WT, Zhang FH, Foley Nelson T, Fischer JE. Hyperammonemia and anorexia in Morris hepatoma-bearing rats. Physiol Behav 1991;50:397-401.
68. Chance WT, Cao L, Nelson JL, Foley-Nelson T, Fischer JE. Hyperammonemia in anorectic tumor bearing rats. Life Sci 1988;43:67-74.
69. Matsuzaki H, Uchiba M, Yoshimura K, et al. Hyperammonemia in multiple myeloma. Acta Haematol 1990;84:130-4.
70. Sauer LA, Stayman JW, Dauchy RT. Amino acid, glucose, and lactic acid utilization in vivo by rat tumors. Cancer Res 1982;42:4090-7.
71. Segura JA, Medina MA, Alonso FJ, Sanchez-Jimenez F, Nunez de Castro I. Glycolysis and glutaminolysis in perfused Ehrlich ascites tumor cells. Cell Biochem Funct 1989;7:7-10.
72. Geigy Scientific Tables, Composition of Blood Basle, Switzerland: Ciba Geigy, 1984.
73. Hagmüller E. Der Stoffwechsel von malignen Kolontumoren beim Menschen Mannheim: Habilitationsschrift, Fakultät für klinische Medizin Mannheim der Universität Heidelberg, 1992.
74. Peters T. Serum albumin. Adv Protein Chem 1985;37:161-245.
75. Peters T. All About Albumin: Biochemistry, Genetics and Medical Applications. San Diego: Academic Press, 1996.
76. Ballmer PE, McNurlan MA, Milne E, et al. Measurement of albumin synthesis in humans: a new approach employing stable isotopes. Am J Physiol 1990;259:E797-803.
77. Princen JMG, Mal-Basks GRP, Yap SH. Restoration effects of glucose refeeding on reduced synthesis of albumin and total protein on disaggregated polyribosomes in the liver of starved rats: evidence for a post-transcriptional control mechanism. Ann Nutr Metab 1983;27:182-93.
78. Tsutsumi T, Nakao K, Mitsuoka S, et al. Regulation of albumin and alpha-fetoprotein gene expression by colloid osmotic pressure in human hepatoma cells. Gastroenterology 1993;104:256-62.
79. Doweiko JP, Nompleggi DJ. Role of albumin in human physiology and pathophysiology. JPEN J Parenter Enteral Nutr 1991;15:207-11.
80. Rothschild MA, Oratz M, Schreiber SS. Serum albumin. Hepatology 1988;8:385-401.
81. Rothschild MA, Oratz M, Mongelli J, Fishman L, Schreiber SS. Amino acid regulation of albumin synthesis. J Nutr 1969;98:395-403.
82. Rothschild MA. Albumin synthesis (first part). New Engl J Med 1972;286:748-57.
83. Yap SH, Hafkenscheid JC, van Tongeren JH. Important role of tryptophan on albumin synthesis in patients suffering from anorexia nervosa and hypoalbuminemia. Am J Clin Nutr 1975;28:1356-63.
84. Krause R, James JH, Ziparo V, Fischer JE. Brain tryptophan and the neoplastic anorexia-cachexia syndrome. Cancer 1979;44:1003-8.
85. Rossi Fanelli F, Cangiano C, Ceci F, et al. Plasma tryptophan and anorexia in human cancer. Eur J Cancer Clin Oncol 1986;22:89-95.
86. Cascino A, Cangiano C, Ceci F, et al. Increased plasma free tryptophan levels in human cancer: a tumor related effect?. Anticancer Res 1991;11:1313-6.
87. Cangiano C, Cascino A, Ceci F, et al. Plasma and CSF tryptophan in cancer anorexia. J Neural Transm Gen Sect 1990;81:225-33.
88. Meguid MM, Muscaritoli M, Beverly JL, Yang ZJ, Cangiano C, Rossi Fanelli F. The early cancer anorexia paradigm: changes in plasma free tryptophan and feeding indexes. J Parenter Enteral Nutr 1992;16:56S-9S.
89. Cangiano C, Testa U, Muscaritoli M, et al. Cytokines, tryptophan and anorexia in cancer patients before and after surgical tumor ablation. Anticancer Res 1994;14:1451-5.
90. Rothschild MA, Oratz M, Schreiber SS. Current concepts of albumin metabolism [review]. Gastroenterology 1970;58:402-8.
91. Ancell, H., Course of lectures on the physiology and pathology of the blood and the other animal fluids. Lancet 1839;1:222-231.
92. Kragh-Hansen U. Structure and ligand binding properties of human serum albumin. Dan Med Bull 1990;37:57-84.
93. Milici AJ, Watrous NE, Stukenbrok H, Palade GE. Transcytosis of albumin in capillary endothelium. J Cell Biol 1987;105:2603-12.
94. Rothschild MA. Albumin synthesis (second of two parts). New Engl J Med 1972;286:816-20.
95. Rothschild MA, Oratz M, Schreiber SS. Extravascular albumin [editorial]. N Engl J Med 1979;301:497-8.
96. Rothschild MA, Oratz M, Schreiber SS. Albumin metabolism. Prog Liver Dis 1972;4:19-29.
97. Poulsen HL. Interstitial fluid concentrations of albumin and immunoglobulin G in normal men. Scand J Clin Lab Invest 1974;34:119-22.
98. Malt RA, Wang CA, Yamazaki Z, Miyakuni T. Stimulation of albumin synthesis by hemorrhage. Surgery 1969;66:65-70.
99. Witte CL, Witte MH, Dumont AE, Cole WR, Smith JR. Protein content in lymph and edema fluid in congestive heart failure. Circulation 1969;40:623-30.
100. Thompson W, Ravdin IS, Frank IL. Effect of hypoproteinemia on wound disruption. Arch Surg 1938;36:500-8.
101. Rhoads JE, Kasinskas W. The influence of hypoproteinemia on the formation of callus in experimental fracture. Surgery 1942;11:38-44.
102. Allman RM, Laprade CA, Noel LB. Pressure sores among hospitalized patients. Ann Intern Med 1986;105:337-42.
103. Doweiko JP, Nompleggi DJ. The role of albumin in human physiology and pathophysiology, Part III: albumin and disease states. JPEN J Parenter Enteral Nutr 1991;15:476-83.
104. Shenoi PM. Postoperative catabolism-using HSA 125I. Br J Surg 1969;56:380.
105. Libertin CR, Weaver P, Mobarhan S, Woloschak GE. Subnormal albumin gene expression is associated with weight loss in immunodeficient/DNA-repair-impaired wasted mice. J Am Coll Nutr 1994;13:149-53.
106. Bennhold H, Peters H, Roth E. Über einen Fall von kompletter Analbuminämie ohne wesentliche klinische Krankheitszeichen. Verh Dtsch Ges Inn Med 1954;60:630-4.
107. Russi E, Weigand K. Analbuminemia. Klin Wochenschr 1983;61:541-5.
108. Watkins S, Madison J, Galliano M, Minchiotti L, Putnam FW. A nucleotide insertion and frameshift cause analbuminemia in an Italian family. Proc Natl Acad Sci USA 1994;91:2275-9.
109. Ogawa K, Yokota K, Sonoda T, Piao ZS, Mori M, Nagase S. Albumin-negative hepatocytes in Sprague-Dawley x analbuminemic F1 rats treated with hepatic carcinogens. Int J Cancer 1988;41:727-31.
110. Nagase S, Shimamune K, Shumiya S. An albumin-deficient rat mutant. Science 1979;205:590-1.
111. Sugiyama K, Emori T, Nagase S. Absence of albumin in tissues of analbuminemic rats. J Biochem 1980;88:1413-7.
112. Shumiya S, Nagase S. Establishment and characteristics of three analbuminemic congenic strains of rats. Exp Anim 1986;35:409-16.
113. Ohta T, Ogawa K, Nagase S. Analbuminemia does not significantly influence hepatocarcinogenesis on comparing F344 rats and a congenic line carrying the analbuminemic mutation. Carcinogenesis 1994;15:227-31.
114. Jain RK. Determinants of tumor blood flow [review]. Cancer Res 1988;48:2641-58.
115. Boucher Y, Baxter LT, Jain RK. Interstitial pressure gradients in tissue-isolated and subcutaneous tumors: implications for therapy. Cancer Res 1990;50:4478-84.
116. Boucher Y, Jain RK. Microvascular pressure is the principal driving force for interstitial hypertension in solid tumors: implications for vascular collapse. Cancer Res 1992;52:5110-4.
117. Jain RK. Transport of molecules in the tumor interstitium [review]. Cancer Res 1987;47:3039-51.
118. Gutmann R, Leunig M, Feyh J, et al. Interstitial hypertension in head and neck tumors in patients: correlation with tumor size. Cancer Res 1992;52:1993-5.
119. Sevick EM, Jain RK. Measurement of capillary filtration coefficient in a solid tumor. Cancer Res 1991;51:1352-5.
120. Sevick EM, Jain RK. Blood flow and venous pH of tissue-isolated Walker 256 carcinoma during hyperglycemia. Cancer Res 1988;48:1201-7.
121. Brown RS, Fisher SJ, Wahl RL. Autoradiographic evaluation of the intra-tumoral distribution of 2-deoxy-D-glucose and monoclonal antibodies in xenografts of human ovarian adenocarcinoma. J Nucl Med 1993;34:75-82.
122. Jain RK, Baxter LT. Mechanisms of heterogeneous distribution of monoclonal antibodies and other macromolecules in tumors: significance of elevated interstitial pressure. Cancer Res 1988;48:7022-32.
123. Jain RK. Physiological barriers to delivery of monoclonal antibodies and other macromolecules in tumors. Cancer Res 1990;50:814s-9s.
124. Jain RK. Delivery of novel therapeutic agents in tumors: physiological barriers and strategies. J Natl Cancer Inst 1989;81:570-6.
125. Jain RK. Vascular and interstitial barriers to delivery of therapeutic agents in tumors. Cancer Metastasis Rev 1990;9:253-66.
126. Ryser HJ. Uptake of protein by mammalian cells: an underdeveloped area. Science 1968;159:390-6.
127. Schumaker VN. Uptake of protein from solution by Amoeba proteus. Exp Cell Res 1958;15:314.
128. Bowers B. Comparison of pinocytosis and phagocytosis in acanthamoeba castellani. Exp Cell Res 1977;110:409-17.
129. Bowers B, Olszewski TE. Pinocytosis in Acanthamoeba castellani: kinetics and morphology. J Cell Biol 1972;53:681-94.
130. Holter H, Holtzer H. Pinocytotic uptake of fluorescein-labelled proteins by various tissue cells. Exp Cell Res 1959;18:421-5.
131. Watts C, Marsh M. Endocytosis: what goes in and how?. J Cell Sci 1992;103:1-8.
132. Bohley P, Seglen PO. Proteases and proteolysis in the lysosome. Experientia 1992;48:151-7.
133. Murnane MJ, Sheahan K, Ozdemirli M, Shuja S. Stage-specific increases in cathepsin B messenger RNA content in human colorectal carcinoma. Cancer Res 1991;51:1137-42.
134. Gabrijelcic D, Svetic B, Spaic D, et al. Cathepsins B, H and L in human breast carcinoma. Eur J Clin Chem Clin Biochem 1992;30:69-74.
135. Nazeer T, Malfetano JH, Rosano TG, Ross JS. Correlation of tumor cytosol cathepsin D with differentiation and invasiveness of endometrial adenocarcinoma. Am J Clin Pathol 1992;97:764-9.
136. Zeillinger R, Swoboda H, Machacek E, et al. Expression of cathepsin D in head and neck cancer. Eur J Cancer 1992;28A:1413-5.
137. Scambia G, Benedetti P, Ferrandina G, Battaglia F, Baiocchi G, Mancuso S. Cathepsin D assay in ovarian cancer: correlation with pathological features and receptors for oestrogen, progesterone and epidermal growth factor. Br J Cancer 1991;64:182-4.
138. Johnson MD, Torri JA, Lippman ME, Dickson RB. The role of cathepsin D in the invasiveness of human breast cancer cells. Cancer Res 1993;53:873-7.
139. Ferrandina G, Scambia G, Benedetti Panici P, et al Cathepsin D in primary squamos laryngeal tumors: correlation with clinico-pathological parameters and receptor status. Cancer Lett 1992;67:133-8.
140. Liaudet E, Garcia M, Rochefort H. Cathepsin D maturation and its stimulatory effect on metastasis are prevented by addition of KDEL retention signal. Oncogene 1994;9:1145-54.
141. Scambia G, Panici PB, Ferrandina G, et al. Clinical significance of cathepsin D in primary ovarian cancer. Eur J Cancer 1994;30A:935-40.
142. Kos J, Smid A, Krasovec M, et al. Lysosomal proteases cathepsins D, B, H, L and their inhibitors stefins A and B in head and neck cancer. Biol Chem Hoppe Seyler 1995;376:401-5.
143. Sivaparvathi M, Sawaya R, Wang SW, et al. Overexpression and localization of cathepsin B during the progression of human gliomas. Clin Exp Metastasis 1995;13:49-56.
144. Duffy JM. Proteases as prognostic markers in cancer. Clin Cancer Res 1996;2:613-8.
145. Boyer MJ, Tannock IF. Lysosomes, lysosomal enzymes, and cancer. Adv Cancer Res 1993;60:269-91.
146. Ghose T, Nairn RC, Fothergill JE. Uptake of proteins by malignant cells. Nature 1962;196:1108-9.
147. Mego JL. Role of thiols, pH and cathepsin D in the lysosomal catabolism of serum albumin. Biochem J 1984;218:775-83.
148. Soreide JA, Lea OA, Kvinnsland S. Cytosol protein content and prognosis in operable breast cancer. Correlations with steroid hormone receptors and other prognostic factors. Breast Cancer Res Treat 1991;20:25-32.
149. Soreide JA, Lea OA, Kvinnsland S. Cytosol albumin content in operable breast cancer. Correlations to steroid hormone receptors, other prognostic factors and prognosis. Acta Oncol 1991;30:797-802.
150. Eagle H, Piez KA. The utilization of proteins by cultured human cells. J Biol Chem 1960;236:1095-7.
151. Jakoby WB, Pastan I. Methods in Enzymology: Cell Culture, Vol. LVIII. San Diego: Academic Press, 1979.
152. Butler M, Dawson M. Cell Culture. Oxford: Bios Scientific, 1992.
153. Moore GE, Woods LK. Culture media for human cells - RPMI 1603, RPMI 1634, RPMI1640 and GEM 1717. Tissue Culture Assoc Manual 1976;3:503-8.
154. Cohn ZA, Parks E. The regulation of pinocytosis in mouse macrophages: factors influencing vesicle formation. J Exp Med 1967;125:213-36.
155. Gordon AH. The role of lysosomes in protein metabolism. In: Dingle JT, editor. Lysosomes in Biology and Pathology, Vol. 3. Amsterdam: North-Holland, 1973:89-137.
156. Hammer JA, Rannels DE. Protein turnover in pulmonary macrophages. Utilization of amino acids derived from protein degradation. Biochem J 1981;198:53-65.
157. Besterman JM, Airhart JA, Low RB, Rannels DE. Pinocytosis and intracellular degradation of exogenous protein: modulation by amino acids. J Cell Biol 1983;96:1586-91.
158. Baserga R. Principles of molecular cell biology of cancer: the cell cycle. In: de Vita VT, S Hellman, SA Rosenberg, editors. Cancer Principles and Practice of Oncology, Vol. 4. Philadelphia: J.B. Lippincott, 1993:60-66.
159. Warren G. Membrane partitioning during cell division. Annu Rev Biochem 1993;62:323-48.
160. Sartorelli AC. Therapeutic attack of hypoxic cells of solid tumors: presidential address. Cancer Res 1988;48:775-8.
161. Less JR, Skalak TC, Sevick EM, Jain RK. Microvascular architecture in a mammary carcinoma: branching patterns and vessel dimensions. Cancer Res 1991;51:265-73.
162. Manz R, Otte J, Thews G, Vaupel P. Relationship between size and oxygenation status of malignant tumors. Adv Exp Med Biol 1983;159:391-8.
163. Vaupel P, Kallinowski F, Okunieff P. Blood flow, oxygen consumption and tissue oxygenation of human tumors. Adv Exp Med Biol 1990;277:895-905.
164. Marx E, Mueller Klieser W, Vaupel P. Lactate-induced inhibition of tumor cell proliferation. Int J Radiat Oncol Biol Phys 1988;14:947-55.
165. Argiles JM, Azcon Bieto J. The metabolic environment of cancer. Mol Cell Biochem 1988;81:3-17.
166. Forster S, Lloyd JB. Solute translocation across the mammalian lysosome membrane. Biochim Biophys Acta 1988;947:465-91.
167. Pisoni RL, Thoene JG. The transport systems of mammalian lysosomes. Biochim Biophys Acta 1991;1071:351-73.
168. Mancini G, Beerens C, Aula PP, Verheijen FW. Sialic acid storage diseases - a multiple lysosomal transport defect for acidic monosaccharides. J Clin Invest 1991;87:1329-35.
169. Baggetto LG. Deviant energetic metabolism of glycolytic cancer cells. Biochimie 1992;74:959-74.
170. Matsuno T. Bioenergetics of tumor cells: glutamine metabolism in tumor cell mitochondria. Int J Biochem 1987;19:303-7.
171. File DeRicco S, Gelbard AS, Cooper AJ, Rosenspire KC, Nieves E. Short-term metabolic fate of L-13Nglutamate in the Walker 256 carcinosarcoma in vivo. Cancer Res 1990;50:4839-44.
172. Moreadith RW, Lehninger AL. The pathways of glutamate and glutamine oxidation by tumor cell mitochondria. J Biol Chem 1984;259:6215-21.
173. Reitzer LJ, Wice BM, Kennell D. Evidence that glutamine, not sugar is the major energy source for cultured HeLa cells. J Biol Chem 1979;254:2669-76.
174. 2 ratios. Biochem J 1987;246:633-9.
175. Gal D, Simpson ER, Porter JC, Snyder JM. Defective internalization of low density lipoprotein in epidermoid cervical cancer cells. J Cell Biol 1982;92:597-603.
176. Clayman RV, Bilhartz LE, Spady DK, Buja LM, Dietschy JM. Low density lipoprotein-receptor activity is lost in vivo in malignantly transformed renal tissue. FEBS Lett 1986;196:87-90.
177. Neu J, Shenoy V, Chakrabarti R. Glutamine nutrition and metabolism: where do we go from here?. FASEB J 1996;10:829-37.
178. Müller-Klieser W, Walenta S, Paschen W, Kallinowski F, Vaupel P. Metabolic imaging in microregions of tumors and normal tissues with bioluminiscence and photon counting. J Natl Cancer Inst 1988;80:842-8.
179. Müeller-Klieser W, Walenta S, Kallinowski F, Vaupel P, Fortmeyer HP. Metabolic imaging in human tumor xenografts in rnu/rnu-rats using bioluminescence. Strahlenther Onkol 1989;165:506-7.
180. Oratz M, Schreiber SS, Rothschild MA. Study of albumin synthesis in relation to urea synthesis. Gastroenterology 1973;65:647-50.
181. Andersson CE, Lonnroth IC, Gelin LJ, Moldawer LL, Lundholm KG. Pretranslational regulation of albumin synthesis in tumor-bearing mice. The role of anorexia and undernutrition. Gastroenterology 1991;100:938-45.
182. Lundholm K, Karlberg I, Schersten T. Albumin and hepatic protein synthesis in patients with early cancer. Cancer 1980;46:71-6.
183. Lundholm K, Edström S, Ekman L, Karlberg I, Bylund A, Schersten T. A comparative study of the influence of malignant tumor on host metabolism in mice and man: evaluation of an experimental model. Cancer 1978;42:453-61.
184. Gelin J, Moldawer LL, Lonnroth C, Sherry B, Chizzonite R, Lundholm K. Role of endogenous tumor necrosis factor alpha and interleukin 1 for experimental tumor growth and the development of cancer cachexia. Cancer Res 1991;51:415-21.
185. Langstein HN, Doherty GM, Fraker DL, Buresh CM, Norton JA. The roles of gamma-interferon and tumor necrosis factor alpha in an experimental rat model of cancer cachexia. Cancer Res 1991;51:2302-6.
186. Fong Y, Moldawer LL, Marano M, et al. Cachectin/TNF or IL-1a induces cachexia with redistribution of body proteins. Am J Physiol 1989;256:R659-65.
187. Brenner DA, Buck M, Feitelberg SP, Chojkier M. Tumor necrosis factor-alpha inhibits albumin gene expression in a murine model of cachexia. J Clin Invest 1990;85:248-55.
188. Morrone G, Cortese R, Sorrentino V. Post-transcriptional control of negative acute phase genes by transforming growth factor beta. EMBO J 1989;8:3767-71.
189. Magielska Zero D, Bereta J, Czuba Pelech B, Pajdak W, Gauldie J, Koj A. Inhibitory effect of human recombinant interferon gamma on synthesis of acute phase proteins in human hepatoma Hep G2 cells stimulated by leukocyte cytokines, TNF alpha and IFN-beta 2/BSF-2/IL-6. Biochem Int 1988;17:17-23.
190. Castell JV, Gomez Lechon MJ, David M, Hirano T, Kishimoto T, Heinrich PC. Recombinant human interleukin-6 (IL-6/BSF-2/HSF) regulates the synthesis of acute phase proteins in human hepatocytes. FEBS Lett 1988;232:347-50.
191. Mulligan HD, Mahony SM, Ross JA, Tisdale MJ. Weight loss in a murine cachexia model is not associated with the cytokines tumour necrosis factor-alpha or interleukin-6. Cancer Lett 1992;65:239-43.
192. Socher SH, Martinez D, Craig JB, Kuhn JG, Oliff A. Tumor necrosis factor not detectable in patients with clinical cancer cachexia. J Natl Cancer Inst 1988;80:595-8.
193. Fujimoto Ouchi K, Tamura S, Mori K, Tanaka Y, Ishitsuka H. Establishment and characterization of cachexia-inducing and non-inducing clones of murine colon 26 carcinoma. Int J Cancer 1995:61:522-8.
194. Muscaritoli M, Meguid MM, Beverly JL, Yang Z, Cangiano C, Rossi Fanelli F. Mechanism of early tumor anorexia. J Surg Res 1996;60:389-97.
195. Roe S, Cooper AL, Morris ID, Rothwell NJ. Mechanisms of cachexia induced by T-cell leukemia in the rat. Metabolism 1996;45:645-51.
196. Norton JA, Moley JF, Green MV, Carson RE, Morrison SD. Parabiotic transfer of anorexia/cachexia in male rats. Cancer Res 1985;45:5547-52.
197. Olson TS, Dice JF. Regulation of protein degradation rates in eukaryotes. Curr Opin Cell Biol 1989;1:1194-200.
198. Baracos VE, DeVivo C, Hoyle DH, Goldberg AL. Activation of the ATP-ubiquitin-proteasome pathway in skeletal muscle of cachectic rats bearing a hepatoma. Am J Physiol 1995;268:E996-1006.
199. Fagan JM, Waxman L, Goldberg AL. Skeletal muscle and liver contain a soluble ATP + ubiquitin-dependent proteolytic system. Biochem J 1987;243:335-43.
200. Attaix D, Taillandier D, Temparis S, et al. Regulation of ATP-ubiquitin-dependent proteolysis in muscle wasting. Reprod Nutr Dev 1994;34:583-97.
201. Temparis S, Asensi M, Taillandier D, et al. Increased ATP-ubiquitin-dependent proteolysis in skeletal muscles of tumor-bearing rats. Cancer Res 1994;54:5568-73.
202. Llovera M, Garcia Martinez C, Agell N, Lopez Soriano FJ, Argiles JM. Muscle wasting associated with cancer cachexia is linked to an important activation of the ATP-dependent ubiquitin-mediated proteolysis. Int J Cancer 1995;61:138-41.
203. Rock KL, Gramm C, Rothstein L, et al. Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules. Cell 1994;78:761-71.
204. Hilt W, Wolf DH. Proteasomes: destruction as a programme. Trends Biochem Sci 1996;21:96-102.
205. Hershko A, Ciechanover A. The ubiquitation system for protein degradation. Annu Rev Biochem 1992;61:761-807.
206. Peters J. Proteasomes: protein degradation machines of the cell. Trends Biochem Sci 1994;19:377-81.
207. Hochstrasser M. Ubiquitin, proteasomes, and the regulation of intracellular protein degradation. Curr Opin Cell Biol 1995;7:215-23.
208. Driscoll J, Goldberg AL. The proteasome (multicatalytic protease) is a component of the 1500-kDa proteolytic complex which degrades ubiquitin-conjugated proteins. J Biol Chem 1990;265:4789-92.
209. Furuno K, Goodman MN, Goldberg AL. Role of different proteolytic systems in the degradation of muscle proteins during denervation atrophy. J Biol Chem 1990;265:8550-7.
210. Medina R, Wing SS, Haas A, Goldberg AL. Activation of the ubiquitin-ATP-dependent proteolytic system in skeletal muscle during fasting and denervation atrophy. Biomed Biochem Acta 1991;50:347-56.
211. Tiao G, Fagan J, Roegner V, et al. Energy-ubiquitin-dependent muscle proteolysis during sepsis in rats is regulated by glucocorticoids. J Clin Invest 1996;97:339-48.
212. Wing SS, Haas AL, Goldberg AL. Increase in ubiquitin-protein conjugates concomitant with the increase in proteolysis in rat skeletal muscle during starvation and atrophy denervation. Biochem J 1995;307:639-45.
213. England BK, Price SR. Acidosis and glucocorticoids interact to provoke muscle protein and amino acid catabolism. Blood Purif 1995;13:147-52.
214. Voisin L, Breuille D, Combaret L, et al. Muscle wasting in a rat model of long-lasting sepsis results from the activation of lysosomal, calcium-activated, and ubiquitin-proteasome proteolytic pathways. J Clin Invest 1996;97:1610-7.
215. Fang CH, Tiao G, James H, Ogle C, Fischer JE, Hasselgren PO. Burn injury stimulates multiple proteolytic pathways in skeletal muscle, including the ubiquitin-energy-dependent pathway. J Am Coll Surg 1995;180:161-70.
216. Medina R, Wing SS, Goldberg AL. Increase in levels of polyubiquitin and proteasome mRNA in skeletal muscle during starvation and denervation atrophy. Biochem J 1995;307:631-7.
217. Mitch WE, Medina R, Grieber S, et al. Metabolic acidosis stimulates muscle protein degradation by activating the adenosine triphosphate-dependent pathway involving ubiquitin and proteasomes. J Clin Invest 1994;93:2127-33.
218. Wing SS, Goldberg AL. Glucocorticoids activate the ATP-ubiquitin-dependent proteolytic system in skeletal muscle during fasting. Am J Physiol 1993;264:E668-76.
219. Tawa NEJ, Goldberg AL. Suppression of muscle protein turnover and amino acid degradation by dietary protein deficiency. Am J Physiol 1992;263:E317-25.
220. Tsujinaka T, Fujita J, Ebisui C, et al. Interleukin 6 receptor antibody inhibits muscle atrophy and modulates proteolytic systems in interleukin 6
221. Garcia Martinez C, Llovera M, Agell N, Lopez Soriano FJ, Argiles JM. Ubiquitin gene expression in skeletal muscle is increased during sepsis: involvement of TNF-alpha but not IL-1. Biochem Biophys Res Commun 1995;217:839-44.
222. Abbot WE, Albertson K. The effect of starvation, infection and injury on the metabolic processes and body composition. Ann NY Acad Sci 1963;110:941-64.
223. Cahill GF. Starvation in man. N Engl J Med 1970;282:668-75.
224. Saudek CD, Felig P. The metabolic events of starvation. Am J Med 1976;60:117-26.
225. Laborda J, Naval J, Calvo M, Lampreave F, Uriel J. Alpha-fetoprotein and albumin uptake by mouse tissues during development. Biol Neonate 1989:56:332-41.
226. Dancis J, Lind J, Oratz M, Smolens J, Vara M. Placental transfer of proteins in human gestation. Am J Obstet Gynecol 1961;82:167-71.
227. Kulangara AC, Menon MK, Willmott M. Passage of bovine serum albumin from the uterine lumen into the human foetus. Nature 1965;206:1259-60.
228. Masters CL, Bignold LP, Morgan EH. Plasma protein metabolism and transfer to the fetus during pregnancy in the rat. Am J Physiol 1969;216:876-83.
229. Gitlin D, Koch C. On the mechanisms of maternofetal transfer of human albumin and gamma-G globulin in the mouse. J Clin Invest 1968:47:1204-9.
230. Gitlin D, Kumate J, Morales C, Noriega L, Arevalo N. The turnover of amniotic fluid protein in the human conceptus. Am J Obstet Gynecol 1972;113:632-45.
231. Crutchfield FL, Kulangara AC. Passage of bovine serum albumin from the mother to rabbit blastocysts. I. Passage from the circulation to uterine lumen. J Embryol Exp Morphol 1973;30:459-69.
232. Kulangara AC, Crutchfield FL. Passage of bovine serum albumin from the mother to rabbit blastocysts. II. Passage from uterine lumen to blastocyst fluid. J Embryol Exp Morphol 1973;30:471-82.
233. Chien PF, Smith K, Watt PW, Scrimgeour CM, Taylor DJ, Rennie MJ. Protein turnover in the human fetus studied at term using stable isotope tracer amino acids. Am J Physiol 1993;265:E31-5.
234. Dancis J, Braverman N, Lind J. Plasma protein synthesis in the human fetus and placenta. J Clin Invest 1957;36:398-404.
235. Gitlin D, Perricelli A. Synthesis of serum albumin, prealbumin, alpha-foetoprotein, alpha-1-antitrypsin and transferrin by the human yolk sac. Nature 1970;228:995-7.
236. Gitlin D, Boesman M. Sites of serum alpha-fetoprotein synthesis in the human and in the rat. J Clin Invest 1967;46:1010-6.
237. Gitlin D, Boesman M. Serum alpha-fetoprotein, albumin, and gamma-G-globulin in the human conceptus. J Clin Invest 1966;45:1826-38.
238. Maurizi MR. Proteases and protein degradation in Escherichia coli. Experientia 1992;48:178-201.
239. Neidhardt FC. Salmonella: Cellular and Molecular Biology. Washington, DC: American Society for Microbiology, 1996.
240. Lämmler C. Isolation and characterization of a specific receptor for human albumin on a group L Streptococcus. Zentralbl Bakteriol Mikrobiol Hyg 1988;A269:237-44.
241. Shorrock PJ, Lambert PA. Binding of fibronectin and albumin to Enterococcus (Streptococcus) faecalis. Microbial Pathogenesis 1989;6:61-7.
242. Lämmler C, Alaboudi A, Hildebrand A. Characterzation of albumin-binding properties of peptostreptococcus magnus. Can J Microbiol 1989;35:614-8.
243. Shorrock PJ, Lambert PA. Binding of fibronectin and albumin to Enterococcus (Streptococcus) faecalis. Microbial Pathogenesis 1989;6:61-7.
244. Schmidt KH, Mann K, Cooney J, Kohler W. Multiple binding of type 3 streptococcal M protein to human fibrinogen, albumin and fibronectin. FEMS Immunol Med Microbiol 1993;7:135-43.
245. Sippel K, Lämmler C. Further studies on immunoglobulin G- and albumin-binding properties of streptococci of serological group L. Zentralbl Veterinärmed 1995;B42:421-6.
246. Johansson MU, de Chateau M, Bjorck L, Forsen S, Drakenberg T, Wikstrom M. The GA module, a mobile albumin-binding bacterial domain, adopts a three-helix-bundle structure. FEBS Lett 1995;374:257-61.
247. Avila JL. Intracellular digestion of endocytosed proteins as a source of amino acids for protein synthesis in Trypanosoma cruzi. Subcell Biochem 1992;18:189-234.
248. Russell DG, Xu S, Chakraborty P. Intracellular trafficking and the parasitophorous vacuole of Leishmania mexicana-infected macrophages. J Cell Sci 1992;103:1193-210.
249. Burns ER, Pollack S. P. falciparum infected erythrocytes are capable of endocytosis. In Vitro Cell Dev Biol 1988;24:481-6.
250. Pouvelle B, Spiegel R, Hsiao L, et al. Direct access to serum macromolecules by intraerythrocytic malaria parasites. Nature 1991;353:73-5.
251. Loyevsky M, Lytton SD, Mester B, Libman J, Shanzer A, Cabantchik ZI. The antimalarial action of desferal involves a direct access route to erythrocytic (Plasmodium falciparum) parasites. J Clin Invest 1993;91:218-24.
252. Bennett MW, Caulfield JP. Schistosoma mansoni: ingestion of dextrans, serum albumin, and IgG by schistosomula. Exp Parasitol 1991;73:52-61.
253. Shapiro SZ, Webster P. Coated vesicles from the protozoan parasite Trypanosoma brucei: purification and characterization. J Protozool 1989;36:344-9.
254. Morgan GA, Laufman HB, Otieno Omondi FP, Black SJ. Control of G1 to S cell cycle progression of Trypanosoma brucei S427c11 organisms under axenic conditions. Mol Biochem Parasitol 1993;57:241-52.
255. Kattenbach WM, Pimenta PF, de Souza W, Pinto da Silva P. Giardia duodenalis: a freeze-fracture, fracture-flip and cytochemistry study. Parasitol Res 1991;77:651-8.